products-page-bottom-left-box

Albonz

Shrezar Healthcare Nig. Ltd
Onike, Yaba, Lagos, Nigeria.
Email: info@shrezarhealth.com
Tel: 234 1 7929821, 234 1 4548179

Brand Name

Albonz

Manufacturer

SHREECHEM PHARMACEUTICALS PVT. LTD. R-914/915, T.T.C. lndl. Area, Navi Mumbai. 400701, INDIA.

Therapeutic Class

Anthelmintics

Dosage Form, Composition & NAFDAC Registration Number (NRN)

Tablet(NRN: A4-9377): Each tablet contains: Albendazole USP 400 mg Excipients q.s.

Pack size: blister Pack of 1 Tablet.

Pharmacology

Albendazole is a benzimidazole carbamate with anthelmintic and antiprotozoal activity against intestinal and tissue parasites. Animal studies have shown that albendazole exhibits vermicidal, ovacidal and larvacidal activity and exerts its anthelmintic effect by inhibiting tubulin polymerization.

This causes the disruption of the helminth metabolism, including energy depletion, which immobilises and then kills the susceptible helminth. In man, after oral administration, albendazole is absorbed and completely metabolized.

Indications

Neurocysticercosis

ALBONZ TABLET is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm. Taenia solium.

Hydatid Disease

ALBONZ TABLET is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.

Contra-indications

ALBONZ TABLET is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of Albendazole.

Precautions/Warnings

WARNING: It has been noted that leucopaenia has occurred when used for periods longer than recommended. In order to avoid administering albendazole during early pregnancy, women of childbearing age should initiate treatment during the first week of menstruation or after a negative pregnancy test.

PRECAUTIONS: Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of anticysticeral therapy. Cysticercosis may, in rare cases, involve the retina.

Before initiating therapy for neurocysticercosis, the patient should be examined for the presence of retinal lesions. If such lesions are visualized, the need for anticysticeral therapy should be weighed against the possibility of retinal damage caused by albendazole-induced changes to the retinal lesion.

Pregnancy and lactation

Pregnancy Category C.

Albendazole has been shown to be teratogenic (to cause embryotoxicity and skeletal malformations) in pregnant rats and rabbits. There are no adequate and well-controlled studies of albendazole administration in pregnant women. Albendazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

Albendazole is excreted in animal milk. It is not known whether it is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when albendazole is administered to a nursing woman.

Interactions

Adverse Effects

Side effects of albendazole tablet include gastrointestinal discomfort, diarrhoea, headache and dizziness. Hypersensitivity reactions including rash. pruritus and urticaria have been reported less frequently.

Dosage & Administration

Dosing of ALBONZ TABLET will vary, depending upon which of the following parasitic infections is being treated. In young children, the tablets should be crushed or chewed and swallowed with a drink of water. 

 Indications   Patient Weight   Dose   Duration 
 Hydatid Disease   60 kg or greater   400 mg twice daily with meals

 28-day cycle followed by

 a 14-day albendazole-free interval;  

 For a total of 3 cycles. 

 Less than 60 kg

 15 mg/kg/day 

 given in divided doses twice daily with meals 

 (maximum total daily Dose 800 mg)

 Neurocysticercosis   60 kg or greater  400 mg twice daily with meals  8-30 days
 Less than 60 kg

 15 mg/kg/day

 given in divided doses twice daily with meals

 (maximum total daily dose 800 mg)

Patients being treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

OVERDOSE:

In case of overdosage, symptomatic therapy (e.g., gastric lavage and activated charcoal) and general supportive measures are recommended.

Storage/Handling Recommendations

 Store between 15o to 30oC in a dry place. Protect from light. Keep all medicine out of reach of Children.

Review Date

2015-10-12 06:10:44